Teva Pharmaceuticals Issues Statement on a Statement by U.S. Department of Health and Human Services Secretary Kathleen Se

NORTH WALES, Pa.--(BUSINESS WIRE)-- We commend the FDA for making the recommendation to approve providing women with increased over-the-counter (OTC) access to Plan B One-Step® and we are disappointed that at this late date, the Department of Health and Human Services has come to a different conclusion. We have not yet received the Complete Response Letter at this time. We will review the letter when we receive it and then determine our next steps.



CONTACT:

Media:
Teva USA
Denise Bradley, 215-591-8974
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  FDA  General Health

MEDIA:

Suggested Articles

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.